Ethics declarations Competing interests HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work)
The nomenclature commonly used is as follows: N-N-Ncap-N1-N2-N3-N4 (XhS/TXXDh, with h: hydrophobic residue and X: non conserved residue) (Richardson and Richardson, 1988)
Membranes were blocked with a quick blocker for 10 min, followed by overnight incubation with respective primary antibodies at 4 C
It is an utmost privilege to dedicate this landmark scientific publication in the honor of Verdis L